Part of the special news roundup of DCAT member companies for the DCAT Week ’17 Special Edition of DCAT Value Chain Insights (April 5, 2017)

Dr. Reddy’s Laboratories expanded its commercial operations in Europe with the introduction of its generic drug portfolio in France, where the first products were scheduled to be made available to the hospital market in March 2017. The company plans to supply generic oncology drugs and anti-infectives, including antimycotics, to hospitals in France.

Dr. Reddy’s also recently launched select products of its hospital portfolio in Italy and Spain and is looking to further strengthen its presence in the two countries with the launch of anti-HIV products in 2017.

The company has a portfolio of injectables and complex generics and has two research and development centers, one manufacturing facility, and a packaging and storage facility in Europe.

Source: Dr. Reddy’s Laboratories